Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CYTK 
Cytokinetics Inc (CYTK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: CYTK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $72.55
1 Year Target Price $72.55
| 9 | Strong Buy |
| 9 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 49.37% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.14B USD | Price to earnings Ratio - | 1Y Target Price 72.55 |
Price to earnings Ratio - | 1Y Target Price 72.55 | ||
Volume (30-day avg) 21 | Beta 0.59 | 52 Weeks Range 29.31 - 61.38 | Updated Date 07/4/2025 |
52 Weeks Range 29.31 - 61.38 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -9856.3% |
Management Effectiveness
Return on Assets (TTM) -34.12% | Return on Equity (TTM) -572.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3956358787 | Price to Sales(TTM) 215.39 |
Enterprise Value 3956358787 | Price to Sales(TTM) 215.39 | ||
Enterprise Value to Revenue 205.87 | Enterprise Value to EBITDA -15.82 | Shares Outstanding 119427000 | Shares Floating 118832545 |
Shares Outstanding 119427000 | Shares Floating 118832545 | ||
Percent Insiders 0.72 | Percent Institutions 119.58 |
Upturn AI SWOT
Cytokinetics Inc
Company Overview
History and Background
Cytokinetics, Inc. was founded in 1997. It is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.
Core Business Areas
- Cardiology: Focuses on developing treatments for heart failure and related cardiovascular conditions, including hypertrophic cardiomyopathy (HCM).
- Neuromuscular Diseases: Develops therapies for neuromuscular disorders, such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
Leadership and Structure
Robert I. Blum serves as the President and CEO. The company has a board of directors overseeing the management team and strategy.
Top Products and Market Share
Key Offerings
- Aficamten (HCM treatment): Aficamten is an oral selective cardiac myosin inhibitor, designed to reduce the number of active actin-myosin cross-bridges within the sarcomere. Aficamten reduces excessive contractility, improves cardiac energetics, and relieves heart failure symptoms in HCM patients. Competitors are mavacamten (Camzyos by Bristol Myers Squibb (BMY)) and Metoprolol (Betaloc by AstraZeneca (AZN)). Market share data is not yet available as the product is not yet on the market. Currently in Phase 3 clinical trials.
- Omecamtiv Mecarbil (Cardiac Myosin Activator): A selective cardiac myosin activator intended to increase cardiac contractility. Revenue streams are pending potential regulatory approval and commercialization. Competitors include established heart failure medications such as diuretics, ACE inhibitors, beta-blockers, and ARNI (angiotensin receptor-neprilysin inhibitors). Market share data is not yet available as the product is not yet on the market, but if approved it will target a portion of the heart failure market. The drug is currently owned by Bristol Myers Squibb (BMY).
- Relyvrio (ALS treatment): Partnered with Amylyx Pharmaceuticals to develop and commercialize Relyvrio for ALS. The market share of Relyvrio is estimated to be around 10% based on recent analysis reports. Key competitors are Edaravone (Radicava by Mitsubishi Tanabe Pharma) and Riluzole (Rilutek by Sanofi).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It involves the discovery, development, and commercialization of new therapies and medications.
Positioning
Cytokinetics positions itself as an innovator in muscle biology, focusing on novel treatments for cardiovascular and neuromuscular diseases. Its competitive advantage lies in its expertise in muscle physiology and its pipeline of unique muscle-targeted therapies.
Total Addressable Market (TAM)
The TAM for heart failure and neuromuscular diseases is significant, potentially exceeding $40 billion. Cytokinetics is positioned to capture a portion of this market with its innovative therapies.
Upturn SWOT Analysis
Strengths
- Strong pipeline of muscle-targeted therapies
- Expertise in muscle biology
- Strategic partnerships with major pharmaceutical companies
- Experienced management team
Weaknesses
- Dependence on clinical trial outcomes
- High R&D expenses
- Reliance on partnerships for commercialization
- Limited revenue streams until product approval
Opportunities
- Expanding pipeline to address additional muscle-related diseases
- Potential for regulatory approval of key drug candidates
- Strategic acquisitions to broaden product portfolio
- Growing demand for innovative therapies in cardiovascular and neuromuscular diseases
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Patent expiration and generic competition
Competitors and Market Share
Key Competitors
- BMY
- AZN
- MYL
- SNY
Competitive Landscape
Cytokinetics has a competitive advantage in muscle biology, but faces stiff competition from established pharmaceutical giants with broader product portfolios and greater resources.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Cytokinetics' growth has been characterized by periods of intense R&D activity and strategic partnerships.
Future Projections: Future growth projections depend heavily on the success of its late-stage clinical trials and regulatory approvals. Analyst estimates are readily available from financial news sources.
Recent Initiatives: Recent initiatives include advancing aficamten through clinical trials, and strengthening relationships with key pharmaceutical partners.
Summary
Cytokinetics is a promising biopharmaceutical company focused on muscle-targeted therapies. The company boasts a solid pipeline, yet it is dependent on clinical trial outcomes and regulatory approvals. Partnerships are also crucial for their commercialization strategy. Cytokinetics needs to navigate intense competition and manage high R&D costs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Financial News Outlets
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytokinetics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2004-04-29 | CEO, President & Director Mr. Robert I. Blum | ||
Sector Healthcare | Industry Biotechnology | Full time employees 498 | Website https://www.cytokinetics.com |
Full time employees 498 | Website https://www.cytokinetics.com | ||
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.